Osimertinib in NSCLC: Real-World Data From New Zealand

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• EGFR tyrosine kinase inhibitors (TKIs) are superior to chemotherapy for EGFR-mutant non-small cell lung cancer (NSCLC).
• Acquired resistance, often due to EGFR T790M mutation, is a common cause of disease progression on EGFR TKI therapy.
• Osimertinib, a third-generation EGFR TKI, offers improved outcomes for EGFR T790M-positive NSCLC compared to chemotherapy.

Purpose of the Study:

• To retrospectively review the clinical outcomes of patients with EGFR T790M-mutated NSCLC treated with osimertinib in New Zealand.
• To evaluate the efficacy and tolerability of osimertinib in a compassionate access program setting.

Main Methods:

• Retrospective review of clinical data from 37 patients with EGFR T790M-mutated NSCLC who received osimertinib.
• EGFR T790M mutation status confirmed via biopsy or circulating tumor DNA (ctDNA).
• Survival outcomes calculated from the initiation of osimertinib treatment.

Main Results:

• An overall response rate of 70% was observed (26/37 patients).
• Median progression-free survival (PFS) was 14.6 months, with 62% PFS at 12 months.
• Osimertinib was generally well-tolerated, with common adverse events including grade 1 gastrointestinal and skin toxicity.

Conclusions:

• Osimertinib is an effective treatment option for New Zealand patients with EGFR T790M-mutated NSCLC who have progressed on prior therapies.
• The study supports the use of osimertinib in this patient population, demonstrating favorable efficacy and tolerability.